Introduction
============

Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery and adjuvant chemotherapy has become the standard treatment for locally advanced rectal cancer.[@b1-cmar-10-3101]--[@b4-cmar-10-3101] After nCRT, 10%--30% patients could achieve pathological complete response (pCR) and 2%--50% patients could achieve complete clinical response.[@b5-cmar-10-3101]--[@b7-cmar-10-3101] However, among the pCR or complete clinical response patients, outcomes of patients with a wait-and-see policy were similar to those who underwent surgery.[@b6-cmar-10-3101],[@b8-cmar-10-3101] According to previous studies, selective patients with stage ypT0-2N0 are considered eligible candidates for organ preservation.[@b9-cmar-10-3101]--[@b11-cmar-10-3101] Accurate prediction of the response to nCRT is still under investigation. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are cancer antigens that might elevated in the serum of patients with colorectal cancer and has been routinely used in the staging of patients with rectal cancer.[@b12-cmar-10-3101]--[@b14-cmar-10-3101] There have been some reports investigating whether pretreatment CEA and CA 19-9 level could predict pathological responses to nCRT in rectal cancer.[@b15-cmar-10-3101]--[@b17-cmar-10-3101] However, the combination of or the changes in the level of CEA and CA19-9 have not been investigated among locally advanced rectal cancer patients with stage ypT0-2N0 after nCRT. The purpose of this study was to assess the predictive role of CEA and CA19-9 in tumor response of nCRT for individualized treatment strategy, especially for organ-sparing management after nCRT and for patients on a wait-and-see policy.

Materials and methods
=====================

Ethics statement
----------------

Although patients' consents were not specifically obtained for this analysis, all information was retrospectively extracted in the context of compliance with the ethical standards of the institutional and/or national research committees and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Patient medical records were analyzed retrospectively, with no individual patient identifiable information used. Therefore, The Fujian Medical University Union Hospital Ethic Review Board deemed patients' consents unnecessary.

Patients and clinical parameters
--------------------------------

The retrospective study was approved by the Fujian Medical University Union Hospital Ethic Review Board. Clinicopathological parameters of 674 patients were obtained from our maintained database. These patients underwent nCRT followed by total mesorectal excision (TME) at our institution between September 2007 and April 2016. The clinicopathological parameters include age, gender, levels of CEA, levels of CA19-9, treatment modality, clinical tumor-node-metastasis staging (cTNM), pathological tumor-node-metastasis staging after the neoadjuvant treatment (ypTNM). The pretreatment parameters were collected one week before the nCRT began, and the post-treatment parameters were defined as changes in the levels of the preoperative parameters 6--8 weeks after nCRT. Patients were staged according to the seventh edition of the American Joint Committee on Cancer Staging Manual. Clinical T and N staging classification were determined according to magnetic resonance imaging and endoscopic ultrasonography.

Treatment
---------

The definitions of gross tumor volume (GTV), clinical target volume (CTV), and planning target volume (PTV) have been published previously.[@b18-cmar-10-3101] The GTV was calculated based on clinical information, including digital rectal examination, endoscopy ultrasound, and abdominopelvic magnetic resonance imaging. The CTV included a minimum of a 3 cm craniocaudal margin to the GTV in addition to the entire mesorectum, presacral, and internal iliac lymph node drainage regions. The neoadjuvant radiotherapy regimen consists of 3-dimensional conformal radiotherapy and intensity-modulated radiation therapy. Forty-five Gy was delivered to PTV of CTV in 25 fractions. A dose of 50.4 Gy was delivered to PTV of GTV with 3-dimensional conformal radiotherapy in 28 fractions, while 50 Gy was delivered to PTV of GTV with intensity-modulated radiation therapy in 25 fractions. The chemotherapeutic regimens with dosages were as follows: 1) FOLFOX4: oxaliplatin 85 mg/m^2^ intravenous (IV), Day 1, leucovorin 200 mg/m^2^ IV ×2 days, 5-FU 400 mg/m^2^ IV bolus ×2 days, then 600 mg/m^2^/d ×2 days continuous infusion. This was repeated every 2 weeks for a total of 6 months of perioperative therapy. 2) mFOLFOX6: oxaliplatin 85 mg/m^2^ IV Day 1, leucovorin 400 mg/m^2^ IV, 5-FU 400 mg/m^2^ IV bolus on Day 1, then 1,200 mg/m^2^/d ×2 days continuous infusion. This was repeated every 2 weeks for a total of 6 months of perioperative therapy. 3) CapeOX: oxaliplatin 130 mg/m^2^ IV, Day 1, capecitabine 1,000 mg/m^2^ twice daily, Days 1--14 every 3 weeks. This was repeated every 3 weeks for a total of 6 months of perioperative therapy. The neoadjuvant 5-FU based or capecitabine-based chemotherapy was initiated on the first day of radiotherapy. Also, TME was performed 6--8 weeks after the end of nCRT.

Data analysis
-------------

In this study, we defined pre--post-CEA ratio as pretreatment CEA to posttreatment CEA ratio and pre--post-CA19-9 ratio as pretreatment CA19-9 to posttreatment CA19-9 ratio. Downstaging was defined as a transition from the pretreatment clinical stage II--III (cT3-4NanyM0) to the pathologic staging of surgical specimen ypStage 0--I (ypT0-2N0M0). pCR was defined as the absence of tumor cells. The receiver operating characteristic (ROC) curve was generated and Youden's index was calculated to evaluate the ideal cut-off values of pretreatment CEA, pretreatment CA19-9, posttreatment CEA, posttreatment CA19-9, pre--post-CA19-9 ratio, and pre--post-CEA ratio for tumor response prediction. Patients were assigned into 2 groups according to the cut-off value. The association between downstaging, pCR, and clinicopathological parameters was evaluated using the Pearson χ^2^ test. A logistic regression analysis was used to identify significant independent parameters for downstaging. Significant independent parameters were incorporated into a scoring system. *P*-value \<0.05 was considered statistically significant. Statistical analysis was performed using the SPSS software 13.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patients' general characteristics
---------------------------------

Six hundred and seventy-four patients with locally advanced rectal cancer receiving nCRT were enrolled. Among the 674 patients, 444 patients were male, and 230 patients were female, with a median age of 56 at diagnosis. The median pretreatment CA 19-9 and CEA levels were 11.855 and 4.1 U/mL. Baseline characteristics are detailed in [Table 1](#t1-cmar-10-3101){ref-type="table"}.

ROC curves of CEA and CA19-9 for downstaging and pCR
----------------------------------------------------

ROC curve analysis was used to evaluate cut-off values of CEA and CA19-9 for predicting downstaging and pCR. The optimum cut-off values defined by ROC curve for pretreatment CEA, pretreatment CA19-9, posttreatment CEA, post-treatment CEA, pre--post-CEA ratio, and pre--post-CA19-9 ratio to discriminate between patient's downstaging were 5.05 U/mL (area under the curve \[AUC\]: 0.637, 95% CI: \[0.595--0.679\], *P*\<0.0001), 12.6 U/mL (AUC: 0.59, 95% CI: \[0.547--0.633\], *P*\<0.0001), 2.45 U/mL (AUC: 0.604, 95% CI: \[0.562--0.647\], *P*\<0.0001), 1.56 U/mL (AUC: 0.608, 95% CI: \[0.565--0.651\], *P*\<0.0001), and 1.28 U/mL (AUC: 0.615, 95% CI: \[0.572--0.657\], *P*\<0.0001), respectively. The posttreatment CA19-9 was not a predictive factor of down-staging ([Figure 1](#f1-cmar-10-3101){ref-type="fig"}). Meanwhile, the optimum cut-off value for pretreatment CEA, posttreatment CEA, pre--post-CEA ratio, and pre--post-CA19-9 ratio to discriminate between patients' pCR were 2.85 U/mL (AUC: 0.619, 95% CI: \[0.568--0.670\], *P*\<0.0001), 2.45 U/mL (AUC: 0.628, 95% CI: \[0.577--0.679\], *P*\<0.0001), 1.07 U/mL (AUC: 0.573, 95% CI: \[0.518--0.627\], *P*=0.009), and 0.92 U/mL (AUC: 0.615, 95% CI: \[0.506--0.615\], *P*=0.029), respectively, but pretreatment CA19-9 and posttreatment CA19-9 were not predictive factors of pCR ([Figure 2](#f2-cmar-10-3101){ref-type="fig"}).

Correlations of characteristic parameters with downstaging and pCR
------------------------------------------------------------------

Pearson χ^2^ test was performed to investigate whether CEA and CA19-9 and other characteristic parameters were associated with downstaging. This revealed that pretreatment CEA, pretreatment CA19-9, posttreatment CEA, pre--post-CEA ratio, and pre--post-CA19-9 ratio were significantly associated with downstaging ([Table 2](#t2-cmar-10-3101){ref-type="table"}). Meanwhile, pretreatment CEA, pretreatment CA19-9, pre--post-CEA ratio, and pre-- post-CA19-9 ratio were significantly associated with pCR ([Table 3](#t3-cmar-10-3101){ref-type="table"}).

ROC curves of a 4-factor scoring system for downstaging
-------------------------------------------------------

The logistic analysis showed that pretreatment CA19-9, posttreatment CEA, pre--post-CEA ratio, and pre--post-CA19-9 ratio were significantly associated with downstaging ([Table 4](#t4-cmar-10-3101){ref-type="table"}). A 4-factor scoring system which assigns points to various variables was constructed. According to the regression coefficient values in the logistic analysis, 5 points, 9 points, 6 points, and 5 points were added for pretreatment CA19-9 level lower than 12.6 U/mL, posttreatment CEA level lower than 2.45 U/mL, pre--post-CEA ratio lower than 1.56, and pre--post-CA19-9 ratio lower than 1.28, respectively. The cut-off value of the 4-factor scoring system calculated by ROC curve was 10.5 (AUC: 0.680, 95% CI: \[0.64--0.721\], *P*\<0.0001, sensitivity 76.4%, specificity 53.7%) ([Figure 3](#f3-cmar-10-3101){ref-type="fig"}). AUC of the scoring system was higher than either of the parameters. These results implied that the scoring system was a significant predictor that can be superior to the use of either CEA or CA19-9 alone.

Discussion
==========

Local control and overall survival rate of rectal cancer has markedly improved after TME. However, TME is associated with poor functional outcome and decrease of the quality of life, especially among patients with distal rectal cancer.[@b8-cmar-10-3101],[@b19-cmar-10-3101] nCRT reduced the rate of local recurrence and improved survival. The recurrence rate of ypT2 patients was not higher than the ypT1 or ypT0/Tis patients.[@b11-cmar-10-3101],[@b20-cmar-10-3101] Local excision after nCRT would be a simple and safe alternative to TME in selected patients with stage ypT0-2N0 while preserving the quality of life.[@b11-cmar-10-3101],[@b20-cmar-10-3101]--[@b23-cmar-10-3101] Accurate prediction of the response to nCRT potentially assists in individualized treatment. However, there is a lack of an ideal model that could accurately screen the stage ypT0-2N0 for organ-sparing management.

The serum CEA level is widely used as a tumor marker in rectal cancer patients. Some studies have evaluated the value of CEA in predicting the response to nCRT in rectal cancer.[@b24-cmar-10-3101]--[@b29-cmar-10-3101] However, the cut-off point was defined by the upper limit of normal value as 5 ng/mL rather than using the ROC curve analysis, as was done in the most previous studies. Also, most of the previous studies analyzed the feasibility of pretreatment CEA level or posttreatment CEA level as the indicator for pCR, but few analyzed the combination of pretreatment CEA levels and posttreatment CEA level as the indicator of stage ypT0-2N0 cancer. Our study suggested that pretreatment CEA, posttreatment CEA and pre--post-CEA ratio was significantly associated with the stage ypT0-2N0, and pretreatment CEA and pre--post-CEA ratio was significantly associated with pCR.

Meanwhile, CA 19-9 is another widely used tumor marker in gastrointestinal tumor and is a significant predictor of survival for rectal cancer.[@b30-cmar-10-3101]--[@b32-cmar-10-3101] However, few studies analyzed the association between CA19-9 and nCRT response. Our study suggested that pretreatment CA19-9 and pre--post-CA19-9 ratio were significantly associated with stage ypT0-2N0 tumor, and pre--post-CA19-9 ratio was significantly associated with pCR. The result was similar to a previous study.[@b17-cmar-10-3101]

Previous studies failed to build a scoring system for organsparing management among patients with stage ypT0-2N0 after nCRT. In the present study, multivariate analysis showed pretreatment CA19-9 level, posttreatment CEA level, pre--post-CEA ratio, and pre--post-CA19-9 ratio were significantly correlated with downstaging. A 4-factor scoring system which assigns points to various variables was constructed according to the regression coefficient values in the logistic analysis. The 4-factor scoring system with CA19-9 level, posttreatment CEA level, pre--post-CEA ratio, and pre--post-CA19-9 ratio is a better predictive biomarker related to downstaging to stage 0--I tumor after nCRT in locally advanced rectal cancer patients than using any of the parameters alone.

There are still some limitations in this study. First, the study is subject to selection bias due to retrospective nature of the analysis. Second, the data were derived from a single institution. Last but not least, the discrimination threshold in this study was determined using ROC analysis. However, it should be validated in different cohorts of patients.

Conclusion
==========

The 4-factor scoring system with CA19-9 level, posttreatment CEA level, pre--post-CEA ratio, and pre--post-CA19-9 ratio is a better predictive model related to downstaging to stage 0--I cancer after nCRT in locally advanced rectal cancer patients than using either CEA or CA19-9 alone. Further studies are needed to validate the result.
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###### 

Characteristics of locally advanced rectal cancer patients

  Characteristics values                          Counts
  ----------------------------------------------- -------------------
  Age (years, median \[range\])                   56 (24--85)
  Gender (male/female)                            444/230
  cT classification                               
   cT1                                            1
   cT2                                            35
   cT3                                            253
   cT4                                            385
  cN classification                               
   N0                                             61
   N+                                             613
  cStage                                          
   II                                             55
   III                                            619
  Pretreatment CA19-9 (U/mL, median \[range\])    11.855 (0--1,000)
  Pretreatment CEA (U/mL, median \[range\])       4.1 (0.2--1,000)
  ypT classification                              
   ypT0                                           148
   ypT1                                           38
   ypT2                                           171
   ypT3                                           270
   ypT4                                           47
  ypN classification                              
   ypN0                                           477
   ypN1                                           149
   ypN2                                           28
  ypStage                                         
   pCR                                            136
   I                                              169
   II                                             164
   III                                            178
   IV                                             27
  Posttreatment CA19-9 (U/mL, median \[range\])   10.62 (0--173.2)
  Posttreatment CEA (U/mL, median \[range\])      2.5 (0.2--308)

**Abbreviations:** CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; pCR,.

###### 

Characteristics for downstaging with locally advanced rectal cancer after nCRT

  Variables                     Sum   Downstaging   Not downstaging   *P*-value
  ----------------------------- ----- ------------- ----------------- -----------
  Age (years)                                                         0.796
   \<65                         534   243           291               
   ≥65                          140   62            78                
  Gender                                                              0.634
   Male                         444   198           246               
   Female                       230   107           123               
  cT classification                                                   0.494
   cT1                          1     0             1                 
   cT2                          35    18            17                
   cT3                          253   120           133               
   cT4                          385   167           218               
  cN classification                                                   0.146
   N0                           61    33            28                
   N+                           613   272           341               
  cStage                                                              0.379
   I                            55    28            27                
   III                          619   277           342               
  ypT classification                                                  \<0.0001
   ypT0                         148   141           7                 
   ypT1                         38    33            5                 
   ypT2                         171   131           40                
   ypT3                         270   0             270               
   ypT4                         47    0             47                
  ypN classification                                                  \<0.0001
   ypN0                         477   305           172               
   ypN1                         149   0             149               
   ypN2                         48    0             48                
  ypStage                                                             \<0.0001
   pCR                          136   136           0                 
   I                            169   169           0                 
   II                           164   0             164               
   III                          178   0             178               
   IV                           27    0             27                
  Pretreatment CEA (U/mL)                                             \<0.0001
   \<5.05                       383   214           169               
   ≥5.05                        291   91            200               
  Pretreatment CA19-9 (U/mL)                                          \<0.0001
   \<12.6                       357   189           168               
   ≥12.6                        317   116           201               
  Posttreatment CEA (U/mL)                                            \<0.0001
   \<2.45                       336   185           151               
   ≥2.45                        338   120           218               
  Posttreatment CA19-9 (U/mL)                                         0.066
   \<11.3                       365   177           188               
   ≥11.3                        309   128           181               
  Pre--post-CEA ratio                                                 \<0.0001
   \<1.56                       328   181           147               
   ≥1.56                        346   124           222               
  Pre--post- CA19-9 ratio                                             \<0.0001
   \<1.28                       438   223           215               
   ≥1.28                        236   82            154               

**Abbreviations:** CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; nCRT, neoadjuvant chemoradiotherapy; pCR, pathological complete response.

###### 

Characteristics for pCR with locally advanced rectal cancer after nCRT

  Variables                  Sum   pCR   Not pCR   *P*-value
  -------------------------- ----- ----- --------- -----------
  Age (years)                                      0.442
   \<65                      534   111   423       
   ≥65                       140   25    115       
  Gender                                           0.182
   Male                      444   83    361       
   Female                    230   53    177       
  cT classification                                0.136
   cT1                       1     0     1         
   cT2                       35    8     27        
   cT3                       253   62    191       
   cT4                       385   66    319       
  cN classification                                0.572
   N0                        61    14    47        
   N+                        613   122   491       
  cStage                                           0.752
   II                        55    12    43        
   III                       619   124   495       
  Pretreatment CEA (U/mL)                          \<0.0001
   \<2.85                    251   71    180       
   ≥2.85                     423   65    358       
  Posttreatment CEA (U/mL)                         \<0.0001
   \<2.45                    336   91    245       
   ≥2.45                     338   45    293       
  Pre--post-CEA ratio                              0.006
   \<1.07                    193   52    141       
   ≥1.07                     481   84    397       
  Pre--post-CA19-9 ratio                           0.012
   \<0.92                    240   61    179       
   ≥0.92                     434   75    359       

**Abbreviations:** CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; nCRT, neoadjuvant chemoradiotherapy; pCR, pathological complete response.

###### 

Multivariate analyses of predictors for downstaging with locally advanced rectal cancer after nCRT

  Variables                       Regression coefficient   SE      *P*-value   OR \[95% CI\]
  ------------------------------- ------------------------ ------- ----------- ----------------------
  Pretreatment CA19-9\<12.6       0.379                    0.177   0.33        1.46 (1.032--2.067)
  Posttreatment CEA \<2.45        0.696                    0.184   \<0.0001    2.007 (1.398--2.879)
  Pre--post-CEA ratio \<1.56      0.441                    0.208   0.034       1.555 (1.034--2.34)
  Pre--post-CA19-9 ratio \<1.28   0.38                     0.194   0.049       1.463 (1.001--2.137)
  Constant                        −1.436                                       

**Abbreviations:** CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; nCRT, neoadjuvant chemoradiotherapy.

[^1]: These authors contributed equally to this work
